News

Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial ...

News

Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers

Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.

News

Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer

A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November ...

News

50 Years of Innovation, Progress, and Exceptional Care in Stem Cell Transplantation

Fifty years ago, Brigham and Women's Hospital and Boston Children's Hospital initiated a joint bone marrow transplant program. In the early 1980s, Dana-Farber launched its own transplant program.

News

ASH Preview

Dana-Farber physician-scientists will share research and clinical advances at the 2022 Annual Meeting of the American Society of Hematology (ASH) December 10-13.

Podcast

Episode 1: The Wolf in Sheep's Clothing

The parable of the wolf in sheep’s clothing tale reminds us that things aren’t always as they seem, that bad guys can dress up as good guys to do their bad guy things.